SES
SES, the leader in global content connectivity solutions, announced today that the Ethiosat platform is now broadcasting all channels of the Association of Ethiopian Broadcasters (AEB) and the Ethiopian Broadcasting Corporation (EBC) exclusively, including many of Ethiopia’s most popular channels such as EBS, ETV News and FANA TV. The variety of lifestyle, news, sport and educational channels – more than 90 channels, out of which 21 are in high definition (HD) – from 57 degrees East, offers unmatched quality and convenience previously not experienced by Ethiopians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006278/en/
In December 2020, the Ethiopian Government announced that all satellite TV channels should be moved to SES’s NSS-12 satellite so that Ethiosat can meet the local TV audiences’ desire for local and international news and entertainment channels while fuelling growth in the Ethiopian media sector.
Since then, the AEB and the EBC have had their members migrate their TV channels and broadcast them from one orbital position rather than have their viewers navigate through a multitude of foreign channels.
To support this migration, SES, through its established Elevate Installer Training programme, and supported by local partners Ethiopian Broadcasting Authority (EBA) and Ethiopian Science and Space Institution (ESSTI), has carried out daily training sessions. As a result, there are now 20,000 certified installers from all regions across Ethiopia who are equipped to help Ethiopian viewers repoint their dishes and continue to watch their favourite local channels without any disruption.
“Repointing dishes for millions of TV households across Ethiopia is not an easy feat, and it’s only possible when we have committed partners such as SES. It has taken us slightly less than two months to get our members’ channels moved to Ethiosat via SES’s satellite, and we are pleased with the progress of repointing the antennas so far,” said Amman Fissehazion, Chairman of AEB.
“We can proudly say that Ethiopians now have their own dedicated TV platform hosting exclusively all Ethiopian satellite TV channels,” said Dr Getachew Dinku Godana, Director General of EBA. “In addition to the high-quality content that this platform is offering, the strategic collaboration behind it has contributed to the creation of jobs and a sense of unity among the Ethiopian population.”
“Our commitment to our local partners in Ethiopia has never been stronger. In an incredibly short time frame, together with our local partners, we have managed to train 20,000 installers and have all AEB and EBC channels now broadcast exclusively from Ethiosat,” said Steve Collar, CEO at SES. “However, our work doesn’t stop here. Together with our local team based in Addis Ababa, we will continue to work with our local partners to repoint dishes across the country, while making sure that Ethiosat continues to host the most attractive TV offering comprising local and international channels.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Ethiosat
Ethiosat is Ethiopia’s first dedicated TV platform to host the most popular local channels. Ethiosat’s tagline “Colour Your World” is inspired by the colourfulness of Ethiopian culture and tradition. The logo is a representation of the fact that a dedicated platform has been created for Ethiopia via satellite. You can follow Ethiosat on social media: Facebook (@ethiosatTV), Instagram(@ethiosat) or Telegram (@EthiosaTV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006278/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom